EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy

Zehao Zheng, Jie Mei, Renguo Guan, Jiqi Zhang, Xinhao Xiong, Junyu Gan, Shaohua Li, Rongping Guo

Cancer Immunology, Immunotherapy · 04.06.2024 · 73 (8)

DOI: 10.1007/s00262-024-03713-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 04.06.2024. Verfasst von Zehao Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The liver function reserve has a significant impact on the therapeutic effects of anti-programmed cell death-1 (PD-1) for hepatocellular carcinoma (HCC). This study aimed to comprehensively evaluate the ability of liver-function-based indicators to predict prognosis and construct a novel prognostic score for HCC patients with anti-PD-1 immunotherapy.

Methods

Between July 2018 and January 2020, patients diagnosed with HCC who received anti-PD-1 treatment were screened for inclusion in the study. The valuable prognostic liver-function-based indicators were selected using Cox proportional hazards regression analysis to build a novel liver-function-indicators-based signature (LFIS). Concordance index (C-index), the area under the receiver operating characteristic (ROC) curve (AUC), and Kaplan–Meier survival curves were utilized to access the predictive performance of LFIS.

Results

A total of 434 HCC patients who received anti-PD-1 treatment were included in the study. The LFIS, based on alkaline phosphatase-to-albumin ratio index, Child–Pugh score, platelet-albumin score, aspartate aminotransferase-to-lymphocyte ratio index, and gamma-glutamyl transpeptidase-to-lymphocyte ratio index, was constructed and identified as an independent risk factor for patient survival. The C-index of LFIS for overall survival (OS) was 0.692, which was higher than the other single liver-function-based indicator. The AUC of LFIS at 6-, 12-, 18-, and 24-month were 0.74, 0.714, 0.747, and 0.865 for OS, respectively. Patients in the higher-risk LFIS group were associated with both worse OS and PFS. An online and easy-to-use calculator was further constructed for better application of the LFIS signature.

Conclusion

The LFIS score had an excellent prognosis prediction ability superior to every single liver-function-based indicator for anti-PD-1 treatment in HCC patients. It is a reliable, easy-to-use tool to stratify risk for OS and PFS in HCC patients who received anti-PD-1 treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularImmune Checkpoint InhibitorsHumansMaleFemalePrognosisMiddle AgedProgrammed Cell Death 1 ReceptorAgedLiver Function TestsRetrospective StudiesSurvival RateLiverImmunotherapyBiomarkers, TumorAdult

Stichwörter der Autor:innen

ALRIAPARAnti-PD-1 therapyGLRHepatocellular carcinomaLiver functionPALSurvival

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Sun Yat-Sen University, Guangzhou, China.
  • Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. lishaoh@sysucc.org.cn.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China. lis…
  • Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. guorp@sysucc.org.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zheng, Z., Mei, J., Guan, R., Zhang, J., Xiong, X., Gan, J., Li, S., & Guo, R. (2024). A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy. Cancer Immunology, Immunotherapy, 73(8). https://doi.org/10.1007/s00262-024-03713-6

Vancouver

Zheng Z, Mei J, Guan R, Zhang J, Xiong X, Gan J, et al. A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy. Cancer Immunology, Immunotherapy. 2024;73(8). doi:10.1007/s00262-024-03713-6

BibTeX
@article{Zheng2024,
  author = {Zheng, Zehao and Mei, Jie and Guan, Renguo and Zhang, Jiqi and Xiong, Xinhao and Gan, Junyu and Li, Shaohua and Guo, Rongping},
  title = {A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  volume = {73},
  number = {8},
  doi = {10.1007/s00262-024-03713-6}
}
Kostenlos starten →